Migration notice:
On August 9th, 2025, Finsight.com market data will be renamed and migrated to CreditFlow, a more intuitive, comprehensive and accessible market data platform for all credit products.
Contact us
for more information.
Market Data
Pricing
Solutions
Log In
Market Overview
Financials
Asset Management & Custody Banks
Parent Companies
Taizhou Huaxin Pharmaceutical Investment Co Ltd
Huaxin Pharmaceutical Hong Kong Co Ltd
2018-2
Huaxin Pharmaceutical Hong Kong Co Ltd (HAXNP) 2018-2
C/P
Sector
Status
Deal Name
Parent
Leads
Region
Date
HYC
FNCL
PRCD
HAXNP 2018-2 (USD 56m)
Taizhou Huaxin Pharmaceutical Investment Co Ltd
BNP
,
CSI
,
EVR
,
GUO
,
...
APAC
Mar 26, 2018
CCY
SIZE (M)
TNR
MTY
RNK
MO
SP
FI
TYPE
BNCH
IPT
GDNC
SPRD
CPN
NIC
PRICE
PVA
30.000
1
Jun-14
Dh. Qiqgxuhgr
-
-
OO+
Hovtm
UJR
-
-
-
6.80%
-
598.00000
Tranche Comments
3 ue: Registration: Adm D Pjdh; Comments: VGF56o Tjo kf 6.8% Sqq. nsm nsnaj Ras G ksak. ZZ+. ZDNN/GNFZA/Ynkjjr Gnsjs/Gsamomrsjj ML/Fasjmja Hajjj/FGA. SNY 100;
Deal Comments
HLR56k mjm xo 6.80% rof 3/15/2021
Guarantor(s)
Khpgfmi Jihwpg Kfhajhzoiipzhh Jgmobijogi Bm Dis
Use of Proceeds
Lqgxs
Refinancing
Yes
Commentary
Upgrade Plan
Deal Flow
Upgrade Plan
Missing something? Tell us.